AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01746719
Drug: Etodolac Capsules USP 300 mg
RxNorm normalized name: etodolac Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg capsule once a day
Trial: NCT01746719
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT03194776
Drug: LLG783
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Trial: NCT03194776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Trial: NCT05306990
Drug: Rosuvastatin 20 Mg Oral Tablet
RxNorm normalized name: rosuvastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients followed up for 3 months
Trial: NCT00716612
Drug: Coenzyme Q 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO Coenzyme Q 10 120 mg QD
Trial: NCT00716612
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po Placebo QD
Trial: NCT01206465
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00057811
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV, IT, or orally
Trial: NCT00057811
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00057811
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT00057811
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00057811
Drug: hydrocortisone sodium succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT02117336
Drug: P1446A-05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death.
Trial: NCT01659138
Drug: SAR339658
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Trial: NCT02191826
Drug: SOM0226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05567536
Drug: Antiplatelet Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
Trial: NCT01248780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
Trial: NCT01248780
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
Trial: NCT02460510
Drug: 3% hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00333138
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 capsule was taken orally once a day
Trial: NCT00333138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.25 mg capsule was given once daily
Trial: NCT02320721
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Trial: NCT00122057
Drug: antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00798915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1% human albumin in normal saline
Trial: NCT01435330
Drug: BVS857
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04636697
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Trial: NCT01435330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03693404
Drug: Marcaine, Duramorph , ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
Trial: NCT03693404
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will only receive standard of care general anesthesia
Trial: NCT00876486
Drug: Genexol-PM®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
Trial: NCT02032277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Veliparib
Trial: NCT00876486
Drug: Genexol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
Trial: NCT03927443
Drug: SDP-133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop
Trial: NCT00626288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cpr, t.i.d. 12 weeks
Trial: NCT03439137
Drug: MT-6548-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02704767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733836
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00914121
Drug: SKI-606
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00914121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676036
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173782
Drug: Berodual® Respimat ® high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173782
Drug: Berodual® Respimat ® low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173782
Drug: Berodual® MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01663623
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine
Trial: NCT00848016
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT04456686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given IV.
Trial: NCT00551265
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02817230
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01225549
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for nebulisation once daily 7 days
Trial: NCT01033396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT01225549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation once daily 7 days
Trial: NCT00743210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 grams once per day for 3 weeks.
Trial: NCT02659644
Drug: Oral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
Trial: NCT04337632
Drug: Doxorubicin Hydrochloride Liposome Injection+carboplatin
RxNorm normalized name: doxorubicin hydrochloride liposome Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
Trial: NCT03186326
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Trial: NCT03651804
Drug: Non-steroidal anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
Trial: NCT03651804
Drug: Bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
Trial: NCT03651804
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
Trial: NCT03651804
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
Trial: NCT00473083
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Trial: NCT02029846
Drug: Incretin-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: incretin-based drugs
Trial: NCT00473083
Drug: Clindamycin 2% in hydrocortisone 1% lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.
Trial: NCT03169504
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks.
Trial: NCT01874431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02367820
Drug: NKTR-181 BID tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 tablets 100-600 mg twice daily (BID)
Trial: NCT03507465
Drug: Letrozole Plus Low-Dose Metronomic Capecitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Letrozole Plus Low-Dose Metronomic Capecitabine
Trial: NCT03507465
Drug: EC-T
RxNorm normalized name: Spec-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin/Cyclophosphamide Followed by Docetaxel
Trial: NCT02072161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, taken once daily oral
Trial: NCT02072161
Drug: Statin Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Trial: NCT00473083
Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
Trial: NCT03186326
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Trial: NCT01959100
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg x 3/week per os during a meal for a period of 2 years
Trial: NCT01959100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg x 3/week during a meal for a period of 2 years
Trial: NCT03789643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching in appearance to the active drug tablets
Trial: NCT00415740
Drug: ELC200 (carbidopa+levodopa+entacapone)
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02877979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01159574
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Trial: NCT00286182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01787552
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787552
Drug: INC424
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00752570
Drug: AMG 386 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
Trial: NCT00752570
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
Trial: NCT00001416
Drug: CEREDASE™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02344303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00253903
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01458275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - one actuation per nostril
Trial: NCT01233635
Drug: start cozaar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: start cozaar
Trial: NCT01233635
Drug: continue cozaar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continue cozaar
Trial: NCT02419755
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
Trial: NCT02419755
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
Trial: NCT02419755
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally (PO).
Trial: NCT02419755
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV).
Trial: NCT01474486
Drug: Micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
Trial: NCT03839134
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
Trial: NCT02830139
Drug: Oxaliplatin , Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Trial: NCT05002361
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of isotonic saline
Trial: NCT00417066
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00060411
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00060411
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04054830
Drug: Voltaren Ophtha 1 mg/ml, GSK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Trial: NCT04054830
Drug: Monopex 1 mg/ml, Théa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Trial: NCT00111761
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Trial: NCT01515319
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical volume to that of Y242
Trial: NCT02386852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
Trial: NCT00619476
Drug: GEn 1200mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 1200mg/day